Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

CompletedOBSERVATIONAL
Enrollment

297

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Sickle Cell Disease
Trial Locations (11)

10461

Montefiore, New York

19801

Cristiana Care, Wilmington

21205

Johns Hopkins University, Baltimore

27514

University of North Carolina, Chapel Hill

33701

All Children's Hospital, St. Petersburg

35233

University of Alabama Birmingham, Birmingham

43203

Ohio State University, Columbus

44106

University Hospital at Cleveland Medical Center, Cleveland

63110

Washington University of St. Louis, St Louis

77030

University of Texas (Houston), Houston

07936

Beth Israel Hospital, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY